• Wednesday, Jul 08, 2020
  • Last Update : 02:28 am

Britain to provide anti-viral drug remdesivir to some Covid-19 patients

  • Published at 11:29 pm May 26th, 2020
FILE PHOTO: An ampule of remdesivir is pictured during a news conference at the University Hospital Eppendorf (UKE) in Hamburg, Germany, April 8, 2020, as the spread of coronavirus disease (Covid-19) continues. Reuters

The government said the allocation of the drug would be determined by where it would have the greatest benefit

Britain will provide the anti-viral drug emdesivir to certain Covid-19 patients who are most likely to benefit, as part of a collaboration with manufacturer Gilead Sciences, the health ministry said on Tuesday.

The department of health said early data from clinical trials around the world showed that the drug could shorten the recovery time of Covid-19 patients by four days.

“This is probably the biggest step forward in the treatment of coronavirus since the crisis began,” Health Minister Matt Hancock told a government news conference.

He said: “These are very early steps, but we are determined to support the science and back the projects that show promise.”

The government said the allocation of the drug would be determined by where it would have the greatest benefit, but did not say how many patients would be treated.

The U.S. National Institutes of Health (NIH) said last week that data from its trial of remdesivir showed that the drug offers the most benefit for Covid-19 patients who need extra oxygen but do not require mechanical ventilation.

The researchers also said that “given high mortality despite the use of remdesivir,” it is likely that the drug would be more effective in combination with other treatments for Covid-19, the respiratory illness caused by the novel coronavirus.

Stephen Griffin, an associate professor at Leeds University, welcomed the move to use remdesivir, saying: “It would likely mean that the most severe Covid-19 patients will receive it first.”

He said that while this approach was the most ethical, it also meant drug would not be a “magic bullet.”

“We can instead hope for improved recovery rates and a reduction in patient mortality,” Griffin said.

Gilead said it expects results from its own study of remdesivir in patients with moderate Covid-19 at the end of this month.

blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail